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Recent epidemiologic data demonstrate increasing rates of neurosyphilis, particularly among those in 
the community of men who have sex with men and those coinfected with the human immunodeficiency 
virus (HIV). Here we discuss a case of early neurosyphilis and new HIV diagnosis in a 27-year-old 
previously-healthy trans woman presenting for the second time with progressive, ascending weakness 
and cranial nerve VI palsy. Emergency physicians should consider this rare but highly morbid 
diagnosis, given the rising prevalence of neurosyphilis among at-risk patients and those with new 
neurologic deficits. [Clin Pract Cases Emerg Med. 2020;4(1):46–50.]  
INTRODUCTION
Neurosyphilis, an invasion of the central nervous system 
(CNS) by the spirochete Treponema pallidum (T pallidum), can 
affect the brain parenchyma, meninges, and spinal cord. This 
disease has been commonly understood as the consequence 
of chronic, untreated syphilis. Now early neurosyphilis is 
resurging among at-risk populations in the United States (U.S.) 
and abroad. During 2015-2016, the U.S. national syphilis rate 
increased by 17.6% to 8.7 cases per 100,000 population – the 
highest rate reported since 1993.1 The ratio of biologically 
male to female individuals with syphilis also increased from 
1.2 (1996) to 5.7 (2005) per 100,0002; this increase was 
disproportionately seen among those in the community of men 
who have sex with men.3 
By some estimates, up to 75% of new syphilis cases 
were among the men who have sex with men population, 
and approximately half of these individuals were 
coinfected with human immunodeficiency virus (HIV).4,5 
The prevalence of neurosyphilis among HIV-infected 
individuals with untreated syphilis has been reported as 
high as 23.5-40%, as compared to approximately 10% 
in HIV-uninfected individuals.6 Here we present a case 
of neurosyphilis in a reportedly previously-healthy trans 
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woman presenting with progressive, ascending weakness 
and new HIV diagnosis. 
CASE REPORT 
A 27-year-old male-to-female transgender patient with 
no significant medical history presented to the emergency 
department (ED) with three weeks of worsening lower 
extremity weakness and pain that progressed to include 
bilateral upper extremity weakness. She described her left leg 
“giving way” while at work several weeks prior; this episode 
caused a fall, but she was able to continue working and did 
not seek medical attention at that time. Within a week, her 
lower extremity weakness progressed to the point of requiring 
assistance to ambulate to the bathroom. She also developed 
worsening, diffuse left leg and low back pain. 
The patient initially sought care one week prior to 
presentation at an outside hospital with the chief complaint of 
back and leg pain and weakness; she reported that radiographs 
of the lumbar spine were normal, and she was discharged home 
with ibuprofen and muscle relaxants. The patient subsequently 
developed worsening upper extremity weakness such that she 
could not pull herself up in bed. Review of systems indicated 
a 10-pound weight loss and intermittent double vision with 
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What do we already know about this 
clinical entity? 
Neurosyphilis is an invasion of the central 
nervous system by the spirochete Treponema 
pallidum. This disease has been understood as 
a consequence of chronic, untreated disease, 
but can present as a primary infection.
What makes this presentation of disease 
reportable?
This case demonstrates a case of primary 
neurosyphilis with HIV diagnosis in a 
previously-healthy trans woman with 
progressive lower-extremity weakness.
What is the major learning point?  
It is important to consider neurosyphilis 
among HIV-infected patients, as well as 
those within the men who have sex with men 
and transgender communities.
How might this improve emergency 
medicine practice?  
Practitioners should consider neurosyphilis 
in at-risk patients, those with HIV or new, 
unexplained neuro-psychiatric symptoms.
rightward gaze; she denied any rash or lesions, fevers, chills, 
photophobia, headache, neck pain or stiffness, or any recent 
illnesses or vaccinations. The patient endorsed being sexually 
active with one male partner and did not use barrier protection 
during anal intercourse. She denied having prior HIV testing.
Social history was notable for daily cigarette use, but no current 
or past intravenous (IV) drug use. The patient had no family 
history of multiple sclerosis, amyotrophic lateral sclerosis, or 
other neurodegenerative diseases.
The patient had normal vital signs on presentation.
Initial neurologic examination was notable for an alert, 
anxious, cooperative patient with fluent speech, loss of right 
eye abduction with diplopia, leftward tongue deviation, 3/5 
strength in right lower extremity, 1/5 strength in left lower 
extremity, 4/5 strength of bilateral upper extremities, 1+ 
biceps reflexes with absent patellar reflexes bilaterally. She 
was unable to walk due to weakness, and required some 
assistance to move from lying to sitting in bed.
Pertinent findings on serum testing included the 
following: a normal c-reactive protein of 2.98 milligrams 
per deciliter (mg/dL) (reference [ref] 0.0-10.0 mg/dL), an 
elevated erythrocyte sedimentation rate of 123 millimeters 
per hour (mm/hr) (ref 0.0-20.0 mm/hr), a normal white blood 
cell count of 6.3 x109/ liter (L) (ref 4.4-16.0 x109/L) with 
a slight neutrophilic predominance, but without bandemia 
(67.9% neutrophils, 19% lymphocytes 11.2% monocytes 1.4 
eosinophils, 0.5 bands); and an elevated creatinine kinase (336 
international units [IU]/L, ref 20-210 IU/L). Other studies that 
were within normal limits included hemoglobin (13.7 grams 
[G]/dL, ref 11.0-16.3 G/dL); platelet count (231 x109/L, ref 
150-400 x109/L); basic metabolic panel; liver function testing; 
and thyroid stimulating hormone.
A non-contrast computed tomography of the brain was 
obtained and was notable for a 1.5 centimeter-mass within the 
central left nasopharynx but did not show any acute cerebral/
cerebellar findings. Lumbar puncture was performed and 
cerebrospinal fluid (CSF) results included the following: 
normal glucose (56 mg/dL, ref 38-85 mg/dL); elevated protein 
(792 mg/dL, ref 15-45 mg/dL); and pleiocytosis (94 cells, ref 
0-5/cubic millimeters) with 92% lymphocytes (ref 63-99%). 
Ceftriaxone and vancomycin were initiated based on abnormal 
CSF preliminary testing.
Given the significant weight loss and new neurologic 
deficits, we obtained consent for HIV testing, and rapid 
antibody/antigen testing returned positive. A qualitative serum 
rapid plasma reagin (RPR) was sent and found to be positive 
with a titer of 1:16. CSF herpes simplex virus I/II polymerase 
chain reactions were negative. While in the ED, CSF venereal 
disease research laboratory (VDRL) testing was positive with 
a 1:2 titer, at which point 24 million units of IV penicillin G 
was administered. HIV myositis was also considered, although 
creatinine kinase level was only 316 IU/L (ref 20-210 IU/L). 
After a multidisciplinary discussion with neurology and 
immunology, neither steroids nor IV immunoglobulin (IG) 
were administered in the ED pending further imaging and 
serologic evaluation.
Magnetic resonance imaging with and without contrast of 
the brain and spine was notable only for diffuse enhancement 
of cauda equina nerve roots with minimal, associated nerve root 
thickening, but no definite nodularity or clumping (Image).
The patient completed a 14-day course of IV penicillin 
G therapy (24 million units) for neurosyphilis. The initial 
cluster of differentiation 4 (CD4) count was 0.247 K/uL (ref 
0.500-1.800 K/uL) with HIV RNA vial load of 37,811 copies/
mL (ref 20-10,000,000 copies/mL). She was started on a 
once-daily antiretroviral regimen of elvitegravir, cobicistat, 
emtricitabine, and tenofovir alafenamide after resistance testing 
was sent. She also received five days of IVIG due to concern for 
Guillain-Barré syndrome (GBS). It was ultimately unable to be 
determined whether her weakness stemmed from neurosyphilis 
alone, GBS, HIV-related neuropathy, critical illness myopathy, 
or a combination of these. Blood cultures and CSF cultures 
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Image. T2-weighted magnetic resonance imaging of the spine. 
Lower spinal sagittal windows demonstrate diffuse enhancement 
of the cauda equina (white arrow). 
remained negative. Cryptococcal, human T-lymphotrophic virus 
1, and herpes simplex virus testing were negative.
After hospital discharge, the patient required 15 days 
of inpatient physical rehabilitation, but ultimately signed 
out against medical advice. She reported improvement in 
diplopia but continued to have lower extremity weakness 
requiring a walker for mobility and assistance with activities 
of daily living. A three-month follow-up lumbar puncture 
was planned to reassess CSF pleiocytosis and VDRL testing, 
but was not completed. Bloodwork obtained 10 months 
after initial diagnosis included reactive RPR with a titer of 
1:4; negative hepatitis B panel; negative mycobacterium 
tuberculosis testing; and an undetectable HIV RNA viral 
load. Currently, the patient remains lost to in-person follow-
up due to ambulation and transportation difficulties. 
DISCUSSION
Progressive, lower extremity weakness has a wide 
differential diagnosis ranging from isolated neuropathies, 
spinal cord compression syndromes, and inflammatory or 
autoimmune disease (e.g., multiple sclerosis, GBS), to CNS 
infection and oncologic processes. This case highlights the 
importance of considering neurosyphilis among HIV-infected 
patients, as well as those within the men who have sex with 
men and transgender communities. 
Estimates report 20-50% of men who have sex with 
men with syphilis living in major cities have concurrent HIV 
infection.2 Prior or concurrent HIV infection increases risk of 
CNS invasion in early syphilis – a 2004 study demonstrated 
that 2.1% of HIV-infected individuals presented with 
neurosyphilis as their early disease manifestation, while only 
0.6% of HIV-uninfected individuals presented in this manner.7 
The four sub-types of neurosyphilis (Figure) are based on 
natural history of syphilis infection: symptomatic meningitis; 
meningovascular disease; general paresis; and tabes dorsalis. 
CNS infection can present with a broad range of neurologic 
concerns including psychiatric symptoms, dementia, 
headache, stroke-like symptoms, meningismus, progressive 
weakness, and encephalopathy.4,8-10
The diagnostic approach to suspected neurosyphilis 
includes lumbar puncture and serum studies to test for the 
presence of T pallidum in the blood and CSF.4,10  Syphilis 
diagnostic testing can be divided into two categories: non-
treponemal testing – RPR and VDRL; and treponemal testing 
– most commonly, the fluorescent treponemal antibody 
absorption (FTA-ABS) test. Non-treponemal testing detects 
the presence of antibody/antigen to T pallidum proteins, while 
the FTA-ABS tests for the whole organism.4 Nontreponemal 
tests can be falsely non-reactive in late syphilis, while 
treponemal tests remain reactive for life in patients with all 
forms of syphilis, even after treatment.4 
Initial evaluation typically includes serum FTA-ABS 
and CSF VDRL testing (qualitative, then quantitative), as 
well as CSF culture and cell counts. T pallidum antibodies 
(immunoglobulin-G, immunoglobulin-M) can also be obtained 
to evaluate chronicity of syphilis infection.11 Since this case, 
revised U.S. Centers for Disease Control and Prevention 
guidelines recommend starting with treponemal testing.12 HIV 
testing should also be performed if the patient’s status is not 
already established. HIV-infected patients with neurosyphilis 
can present with unique clinical manifestations including 
initial false negative serologic testing due to the prozone 
phenomenon; rapid progression to meningovascular disease; 
and inconsistent CSF leukocytosis. However, CSF testing 
should reveal an elevated protein, and this population is more 
likely to have a Jarisch–Herxheimer reaction – a systemic 
inflammatory response to treatment caused by the rapid 
lysis of treponemal organisms. Individuals with a new HIV 
diagnosis should also undergo appropriate CSF testing for 
opportunistic infections including tuberculosis, herpes simplex 
viruses and, depending on clinical presentation, human 
polyoma virus 2. 
Standard treatment for neurosyphilis includes 18-24 
million units/day of IV penicillin G therapy for 10-14 days.6 
Our patient required a 14-day course of penicillin as well as 
antiretroviral therapy. Repeat CSF testing should be performed 
approximately three months13 after treatment to confirm 
clearance of the T pallidum infection from the CNS. Of note, 
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Figure. Natural history of neurosyphilis. Neuro-invasion occurs in at least 40% of individuals. Clearance occurs in about 70% of individuals. 
The remaining 30% of patients have persistent central nervous system (CNS) infection, also called asymptomatic neurosyphilis. In the pre-
penicillin era, about 20% of individuals with asymptomatic neurosyphilis developed one of the symptomatic forms of neurosyphilis. In the 
penicillin era, the early forms (eg, symptomatic meningitis, meningovasculitis) are more common than the late forms (e.g., dementia and tabes 
dorsalis). Reprinted with permission from Marra CM.4
HIV-infected individuals may fail to clear the anti-treponemal 
antibodies after therapy, but there should be a significant 
decrease in levels as measured by CSF VDRL and plasma 
RPR testing.6,10 Patients also often report persistent neurologic 
symptoms six months after initial diagnosis and treatment.14   
CONCLUSION
Given the rising prevalence of neurosyphilis, emergency 
physicians should consider this “cannot-miss” diagnosis, 
particularly among patients presenting with progressive 
weakness, unexplained psychiatric symptoms, new-onset 
dementia, or focal neurologic findings. These patients should 
also receive HIV testing given the rate of co-infection, unique 
clinical manifestations, and response to treatment.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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